GlassScriptPhysician profile
Iosif Goldman
NPI 1477615466
$4,461.27
in general payments reported to CMS, 2019-2025
33 companies · $477 in 2025
The $477 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $731 · 2020: $608 · 2021: $738 · 2022: $784 · 2023: $513 · 2024: $610 · 2025: $477.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,600.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,600.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $936.90 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $473.65 | 2019-2025 | |
| Nestle Healthcare Nutrition INC. | $467.94 | 2020-2023 | |
| Merck Sharp & Dohme LLC | $384.05 | 2019-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Kowa Pharmaceuticals America, INC. | $245.34 | 2019-2025 | Zoryve |
| Aimmune Therapeutics, INC. | $210.95 | 2024-2025 | Zenpep |
| Amarin Pharma, INC. | $202.67 | 2019-2022 | |
| Novo Nordisk INC | $202.07 | 2019-2025 | Ozempic, Rybelsus |
| Amgen INC. | $189.87 | 2019-2025 | Otezla, Repatha, Repatha |
| Pfizer INC. | $106.82 | 2020-2023 | |
| Allergan, INC. | $101.85 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $86.93 | 2019-2022 | |
| Indivior INC. | $82.50 | 2019 | |
| Idorsia Pharmaceuticals US INC | $76.07 | 2023-2025 | Quviviq, Quviviq |
| Glaxosmithkline, LLC. | $58.52 | 2019-2024 | Arexvy, Shingrix |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $57.62 | 2019-2025 | Mounjaro, Zepbound |
| Abbott Laboratories | $54.83 | 2021-2024 | Freestyle Libre 3 |
| Phadia US INC. | $54.24 | 2021-2024 | Immunocap |
| Astellas Pharma US INC | $51.56 | 2020-2025 | Veozah |
| Novartis Pharmaceuticals Corporation | $48.03 | 2022-2023 | |
| Exact Sciences Corporation | $45.41 | 2025 | Cologuard Collection Kit |
| Corium, LLC | $43.05 | 2022-2023 | Azstarys |
| Sanofi-Aventis U.S. LLC | $41.56 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $40.02 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $38.47 | 2022 | |
| Kyowa Kirin, INC. | $30.36 | 2024-2025 | Crysvita |
| Eisai INC. | $28.92 | 2021-2022 | |
| Seqirus USA INC | $27.38 | 2019 | |
| Mylan Specialty L.P. | $18.93 | 2023 | Yupelri |
| Horizon Therapeutics Plc | $14.32 | 2019 | |
| Daiichi Sankyo INC. | $14.30 | 2022 | |
| Alexion Pharmaceuticals, INC. | $13.46 | 2020 | |
| Sanofi Pasteur INC. | $12.68 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Iosif Goldman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.